Citations

Clear

146 citation(s) found for "Simpson, M".

Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.
Pal, Sumanta K. , Bhatia, Sumeet, Drabkin, Harry A., Costello, Brian A. , Sarantopoulos, John , Lauer, Richard C., Hahn, Noah M. , Sonpavde, Guru , Richey, Stephen , Breen, T., Kremmidiotis, Gabriel, Leske, Annabell F., Doolin, Elizabeth , Bibby, David C. , Iglesias, J. L. Mesías, Azad, Arun , Kanesvaran, Ravindran , Sweeney, Christopher J. , Simpson, Jeremy Andrew , Hutson, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 475-475

10.1200/jco.2015.33.7_suppl.475 Get It

475 Background: The vascular disrupting agent (VDA) BNC105P shows synergy with everolimus in preclinical models. The DisrupTOR-1 trial included a phase I component exploring this combination and a randomized phase II component comparing everolimus with BNC105P (Arm A) to everolimus monotherapy (Arm B) (Pal et al. ESMO 2014). Methods: Pts with clear cell mRCC and 1-2 prior therapies (including ≥1 VEGF-TKI) were randomized in the phase II study component. In Arm A, patients received a 7 day lead-in dose of everolimus followed by dosing with BNC105P. Patients in Arm A had optional blood collections prior to administration of BNC105P and 3 hours after receiving BNC105P. A fluorescence-based assay was used to characterize a broad panel of analytes at each time point. Biomarkers were assessed in both a static and dynamic fashion. For the former, biomarkers were stratified by median value, and progression-free survival (PFS) was compared in resulting subgroups using the Kaplan-Meier method. For the latter, change in biomarker level before and after BNC105P infusion was stratified by median difference, and PFS was compared in resulting subgroups using the Kaplan-Meier method. Results: 139 pts were randomized with 69 and 67 evaluable pts in Arms A and B, respectively. Dynamic biomarkers were assessed in a total of 44 patients who received everolimus with BNC105P. Increases in matrix metalloproteinase-9 (MMP-9) and stem cell factor (SCF) were associated with improved PFS (p=0.0421 and p=0.0291, respectively). Decreases in sex hormone binding globulin (SHBG) and serum amyloid protein (SAP) were associated with improved PFS (p=0.0184 and p=0.0063). With respect to static biomarkers, elevated baseline ferritin and lower baseline IL-8 were associated with improved PFS (p=0.0291 and p=0.0149, respectively). Conclusions: Several static and dynamic biomarkers in the DisrupTOR-1 trial were associated with PFS. A prospective biomarker-driven study examining everolimus with BNC105P selected by baseline IL-8 and ferritin is in development. Clinical trial information: NCT01034631.
Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies
Simpson, Claire L. , Andrade, Mariza de , Mandal, Diptasri , Gaba, Colette , Li, Yafang , You, Ming , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Bailey‐Wilson, Joan E. , de Andrade, Mariza, Musolf, Anthony M. , Yang, Ping , Amos, Christopher I. , de Andrade, Mariza , Wilson, Richard K , Pinney, Susan M

Mayo Clinic

Genes | January 18, 2017 | Volume: 8 | Issue: 1 | Pages: 36

10.3390/genes8010036 | PMID 28106732 Get It

Lung cancer is the deadliest cancer in the United States, killing roughly one of four cancer patients in 2016. While it is well-established that lung cancer is caused primarily by environmental effects (particularly tobacco smoking), there is evidence for genetic susceptibility. Lung cancer has been shown to aggregate in families, and segregation analyses have hypothesized a major susceptibility locus for the disease. Genetic association studies have provided strong evidence for common risk variants of small-to-moderate effect. Rare and highly penetrant alleles have been identified by linkage studies, including on 6q23–25. Though not common, some germline mutations have also been identified via sequencing studies. Ongoing genomics studies aim to identify additional high penetrance germline susceptibility alleles for this deadly disease.
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Bagg, Adam , Frank, Dale , Wu, David , Srkalović, Gordan , Simpson, David , Liu, Amy , Menke, David M. , Lechowicz, Mary Jo , Wong, Raymond , Pierson, Sheila K. , Paessler, Michele, Rossi, Jean‐François, Ide, Makoto , Ruth, Jason R., Croglio, M.P. , Suarez, Alexander , Chadburn, Amy , Colleoni, Gisele W. B. , Jayanthan, Raj , Nabel, Christopher S. , Kelleher, Dermot, Voorhees, Peter M. , Yoshizaki, Kazuyuki , Oksenhendler, Éric , Elenitoba‐Johnson, Kojo S.J. , Lim, Megan S. , Menke, David, Wong, Raymond S M , Uldrick, Thomas S. , Chandrakasan, Shanmuganathan , Rossi, Jean‐François , Krymskaya, Vera P. , Nasta, Sunita , Casper, Corey , Dispenzieri, Angela , Fosså, Alexander , Kurzrock, Razelle , Doǧan, Ahmet , Rhee, Frits van , Jaffe, Elaine S. , Fajgenbaum, David C , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | January 13, 2017 | Volume: 129 | Issue: 12 | Pages: 1646-1657

10.1182/blood-2016-10-746933 | PMID 28087540 Get It

Key Points An international panel established the first ever diagnostic criteria for iMCD based on review of 244 clinical cases and 88 tissue samples. The criteria require multicentric lymphadenopathy with defined histopathology, ≥2 clinical/laboratory changes, and exclusion of iMCD mimics.
Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
Spuls, Phyllis I. , Gerbens, Louise A. A. , Simpson, Eric L. , Apfelbacher, Christian , Thomas, Kim S , Prinsen, C.A.C. , Kobyletzki, L.B. von , Williams, Hywel C , Schmitt, Jochen , collaborators, the HOME initiative, Spuls, P I , Gerbens, L A A , Apfelbacher, C J , Thomas, K S , Chalmers, Joanne R , Singh, Jasvinder A. , collaborators, the HOME initiative

Mayo Clinic

British Journal of Dermatology | November 18, 2016 | Volume: 176 | Issue: 4 | Pages: 979-984

10.1111/bjd.15179 | PMID 27858989 Get It

Abstract 2542: Chromatin remodeling gene ARID1B is linked to familial lung cancer
Mandal, Diptasri , Gaba, Colette , You, Ming , Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Musolf, Anthony M. , Simpson, Claire L. , Andrade, Mariza de , Yang, Ping , Pinney, Susan M. , Amos, Christopher I. , Bailey‐Wilson, Joan E.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 2542-2542

10.1158/1538-7445.am2016-2542 Get It

Abstract Several papers have implicated mutations in the AT-rich interactive domain containing protein 1B (ARID1B) in carcinoma formation in multiple tissue types, including the lung. The ARID1B protein functions as part of SWI/SNF, a multi-subunit chromatin remodeling complex that repositions nucleosomes and may act as a tumor suppressor in cancer. ARID1B is located in a region in 6q that was previously shown to have strong evidence of linkage with lung cancer risk. As it is one of the more promising candidates within the target region, this study presents the viability of ARID1B as a candidate gene for familial lung cancer. Here, we chose individuals from families in our previous linkage study that showed the strongest linkage signal on 6q. 75 individuals from 9 families were sequenced for 37Mb of chromosome 6 from 130Mb to 167Mb using Illumina technology and a custom Agilent kit. Genotypes were imported into GoldenHelix SVS 7 for quality control and dropped if read depth < 10, quality score < 10 or a quality score to read depth ratio < 0.5. Variants with more than 1 Mendelian error were dropped. Variants with a single Mendelian inconsistency were dropped only for that family. Two-point parametric linkage analysis at theta = 0 was performed using R and an implementation of the Elston-Stewart algorithm in the paramlink package using a penetrance model of 0.01/0.1/0.1 (dd/Dd/DD) and a disease allele (D) frequency of 0.01. Family 102 showed strong evidence for linkage near ARID1B. The highest LOD score (1.34) out of all sequenced variants was located near this gene in a known conserved intergenic region between ARID1B and NOX3. Four other LOD scores > 0.7 were found in the intergenic region between these two genes. Two are transcription factor binding sites; two are conserved genomic elements. We also observed two linked intronic variants of ARID1B in this family; an enhancer (LOD = 0.89) and a transcribed region (LOD = 0.73). Two other families (47 and 59) displayed evidence of linkage in ARID1B. Here, the interest is not the value of the LOD scores (top scores were 0.64 and 0.54), but the centering of the linked haplotype around the gene. Family 47 has 60 variants with LODs between 0.64 and 0.61; 45 located within ARID1B or known regulatory regions. Family 59 has 61 variants with LODs between 0.54 and 0.51; 29 located within ARID1B or known regulatory regions The variants appear to be spread evenly throughout ARID1B, suggesting the presence of linked haplotypes. Analyses are currently underway to reconstruct possible haplotypes in these families. The results of this study show that variants in the ARID1B gene at least partially account for the linkage signal on 6q in three of the nine most strongly linked families in our cohort and thus we believe that ARID1B is a plausible candidate gene for further studies involving familial lung cancer. Replication studies using 27 new extended families are currently underway to confirm this initial result. Citation Format: Anthony M. Musolf, Claire L. Simpson, Mariza de Andrade, Diptasri Mandal, Colette Gaba, Ping Yang, Ming You, Elena Y. Kupert, Marshall W. Anderson, Ann G. Schwartz, Susan M. Pinney, Christopher I. Amos, Joan E. Bailey-Wilson. Chromatin remodeling gene ARID1B is linked to familial lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2542.
Maintaining good clinical practice: publication of outcomes and handling of outliers
Ray, Simon , Nishimura, Rick A., Clarke, Sarah , Simpson, Iain , Nishimura, Rick

Mayo Clinic

Heart | June 29, 2016 | Volume: 102 | Issue: 19 | Pages: 1518-1519

10.1136/heartjnl-2016-309452 | PMID 27354277 Get It

Geriatrics Education Team Model Results in Sustained Geriatrics Training in 15 Residency and Fellowship Programs and Scholarship
Denson, Steven, Denson, Kathryn , Brown, Diane , Manzi, Gabriel, Rehm, Judith, Wessel, Bambi, Duthie, Edmund H., Simpson, Deborah

Mayo Clinic

Journal of the American Geriatrics Society | March 29, 2016 | Volume: 64 | Issue: 4 | Pages: 855-861

10.1111/jgs.14040 | PMID 27021702 Get It

Caring for the growing elderly population will require specialty and subspecialty physicians who have not completed geriatric medicine fellowship training to participate actively in patient care. To meet this workforce demand, a sustainable approach to integrating geriatrics into specialty and subspecialty graduate medical education training is needed. This article describes the use of a geriatrics education team ( GET ) model to develop, implement, and sustain specialty‐specific geriatrics curricula using a systematic process of team formation and needs assessment through evaluation, with a unique focus on developing curricular interventions that are meaningful to each specialty and satisfy training, scholarship, and regulatory requirements. The GET model and associated results from 15 specialty residency and fellowship training programs over a 4‐year period include 93% curriculum sustainability after initial implementation, more than half of the programs introducing additional geriatrics education, and more than 80% of specialty GET s fulfilling their scholarship requirements through their curriculum dissemination. Win–wins and barriers encountered in using the GET model, along with the model's efficacy in curriculum development, sustainability, and dissemination, are summarized.
Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders
Mielke, Michelle M. , Milić, Nataša , Weissgerber, Tracey L. , Kantarci, Kejal , Windham, B. Gwen , Simpson, Brittany , White, Wendy M, Simpson, Brittany N, Turner, Stephen T. , Garovic, Vesna D. , White, Wendy , Mosley, Thomas H. , Weissgerber, Tracey L , Milic, N , Mielke, Michelle M , Kantarci, Kejal

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | February 23, 2016 | Volume: 9 | Issue: 2_suppl_1 | Pages: No page available

10.1161/circoutcomes.115.002461 | PMID 26908863 Get It

Background— Hypertensive pregnancy disorders have been associated with subjective cognitive complaints or brain white-matter lesions 5 to 10 years after the hypertensive pregnancy. The long-term effects of hypertensive pregnancies on brain structure and cognitive function remain unknown. Methods and Results— This study included 1279 women who participated in the Family Blood Pressure Project Genetic Epidemiology Network of Arteriopathy (GENOA) study. As part of the ancillary Genetics of Microangiopathic Brain Injury (GMBI) study, a neurocognitive battery was administered; 1075 also had a brain magnetic resonance imaging. A history of a hypertensive pregnancy disorder was obtained by a self-report using a validated questionnaire. Linear models fit with generalized estimating equations were used to assess the association between hypertensive pregnancy disorders and cognition, adjusting for age, race, education, body mass index, smoking, current hypertension, hypertension duration, and family history of hypertension. Regression models for the brain magnetic resonance imaging outcomes also were adjusted for total intracranial volume. Women with histories of hypertensive pregnancy disorders performed worse on all measures of processing speed (Digital Symbol Substitution Test [mean score, 41.2 versus 43.4; P =0.005], Trail Making Test Part A [mean seconds, 45.1 versus 42.2; P =0.035], and Stroop [mean score, 173.9 versus 181.0; P =0.002]) and had smaller brain volumes compared with women with histories of normotensive pregnancies (286 versus 297; P =0.023). Conclusions— Hypertensive pregnancy disorders are associated with worse performance on tests of processing speed and smaller brain volumes decades later. Population-based studies are needed to provide critical insight as to the contribution of hypertensive pregnancies to risk of cognitive decline and dementia.
Abstract LB-189: Genetic Epidemiology of Lung Cancer Consortium: genome-wide association study of familial lung cancer cases
Toledo, Diana Marcela , Mandal, Diptasri , Andrade, Mariza de , Kupert, Elena, Gaba, Colette , Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Franks, Jennifer M. , Simpson, Claire L. , You, Ming , Bailey‐Wilson, Joan E. , Amos, Christopher I. , de Andrade, Mariza

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: LB-189-LB-189

10.1158/1538-7445.am2015-lb-189 Get It

Abstract Several studies have identified common genetic factors that influence susceptibility to lung cancer but no large studies have systematically studied familial lung cancers. The Genetic Epidemiology of Lung Cancer Consortium completed a genome-wide association study (GWAS) using samples from 757 cases and 796 controls, all of European American ancestry, and frequency matched on age and sex. Genotyping was performed by the Center for Inherited Disease Research (CIDR) using an Illumina Human OmniExpressExome-8v1 array. The most significantly associated SNPs were identified in the cases as a whole, and were also stratified by histology (adenocarcinoma and squamous cell carcinoma) and family history (0-1 and 2-5 affected family members). Analysis of all cases and controls identified a large number of SNPs around the CFTR gene that are strongly associated with lung cancer risk. Upon imputation with European Ancestry 1000 genomes data, the most significant SNP in this region is rs43034 (p = 3.89E-07, OR = 0.657) in the promoter region. In addition, an exonic missense SNP, rs213950 (p = 6.32E-07, OR = 0.663), and an intronic SNP with a possible splicing effect, rs213935 (p = 5.20E-07, OR = 0.660) were also identified as possible protective alleles. Analysis by histological subtype identified several rare and exonic SNPs that were specific by histology. We highlight two SNPs, rs114719990 (p = 1.194E-04, OR = 336.8, SETD2, c.3229A>G, p.Thr1077Ala) and rs199710487 (p = 1.124E-04, OR = 366, NTN5, c.656G>A, p.Arg219Gln), that were identified as strongly associated SNPs in cases with histologically confirmed adenocarcinoma, and two SNPs, rs144465058 (p = 1.029E-04, OR = 484.6, ANK3, c.6555G>T, p.Gln2185His) and rs140216112 (p = 1.087E-04, OR = 476, GRIK4, c.1013C>G, p.Ala338Gly), that were identified as top SNPs in cases with histologically confirmed squamous cell carcinoma. The SETD2 gene is thought to be a tumor suppressor gene and variants in this gene have previously been associated with leukemia and glioma (Zhu X et al. 2014, Fontebasso AM et al. 2013), and may now have implications in lung cancer, specifically adenocarcinoma development. In conclusion, we identified SNPs in the CFTR gene that may have a protective effect on lung cancer and several rare and exonic variants that were specific to histology subtype. SNPChrPositionGeneGenomic/ Nucleotide/ Amino acid changeOdds Ratiop-valueCFTR Protective Allelesrs430347117108449CFTRg.117108449T>C; 2.4kb upstream0.6573.89×10−7rs2139507117199533CFTRc.1408G>A; p.Val470Met0.6636.32×10−7rs2139357117178208CFTRc.869+1481A>G0.6605.20×10−7 Citation Format: Diana M. Toledo, Susan M. Pinney, Diptasri Mandal, Mariza de Andrade, Elena Kupert, Jennifer Franks, Colette Gaba, Claire L. Simpson, Ming You, Marshall W. Anderson, Joan E. Bailey-Wilson, Christopher I. Amos, Ann Schwartz. Genetic Epidemiology of Lung Cancer Consortium: genome-wide association study of familial lung cancer cases. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-189. doi:10.1158/1538-7445.AM2015-LB-189
Abstract 4600: Target exome sequencing for disease-causing rare mutations in familial and sporadic lung cancer
Wheeler, David A. , Silverman, Edwin K. , Sanjay, Shete, Tsavachidis, Spiridon, Armstrong, Georgina , Kupert, Elena, Anderson, Marshall W., Li, Yafang , Pikielny, Claudio W. , You, Ming , Gaba, Colette , deAndrade, Mariza, Mandal, Diptasri , Spitz, Margaret R., Liu, Yanhong , Kheradmand, Farrah , Scheurer, Michael E. , Davis, Caleb , Armstrong, Georgina , Bailey‐Wilson, Joan E. , Simpson, Claire L. , Pinney, Susan M. , Amos, Christopher I.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4600-4600

10.1158/1538-7445.am2015-4600 Get It

Abstract Background: Recent genome-wide association studies (GWAS) have identified 28 susceptibility loci for Lung cancer (LC), 32 loci for smoking behavior, 10 loci for chronic obstructive pulmonary disease (COPD), 63 loci for pulmonary function and related phenotypes, totaling 107 GWAS susceptibility loci (as of November 2014). Given the common variants that have been found to be associated with LC in GWAS, targeted-region exome sequencing provides a cost-effective approach for further investigation of high-priority regions of the genome and has the great potential to identify rare causal variants in GWAS loci. Patients and Methods: Using an extreme phenotype approach, we selected 48 sporadic LC patients reporting heavy smoking histories with the presence of severe COPD in whom environmental factors are considered overwhelming, and 54 familial LC cases from families with at least three first-degree relatives with LC who are likely enriched for genomic signal, to search for the disease-causing rare mutations within the target 107 GWAS loci using exome sequencing data. Results: By focusing on exome profiles of these target 107 loci, we identified two disease-causing rare mutations on 6p21.32 TNXB p. Arg504His and 10q25.1 CCDC147 p.Arg696Cys. The homozygous Arg504His mutation presented in four familial and one sporadic LC cases. Notably, the minor allele frequency (MAF) of this variant in Caucasians from 1000 Genomes is very rare (<0.001). The heterozygous CCDC147 Arg696Cys variant were identified in two familial cases and one sporadic case. The MAF for this variant in the Caucasians from 1000 Genomes is 0.004. Both deleterious changes lead to truncation of the putative proteins, which disrupts the predicted domain and alters the cellular localization. We also observed several other suggestive rare mutations on G7C, TNS1, DBH1, and CHRNA5. Conclusion: Our target exome sequencing results demonstrate novel highly disruptive LC risk-conferring TNXB and CCDC147 mutations. Since the rare variants have appreciable effects on disease risk prediction, families and patients may warrant screening for mutations in TNXB and CCDC147 (if validated) to assess their potential LC risk. Citation Format: Yanhong Liu, Farrah Kheradmand, Michael Scheurer, Caleb Davis, David Wheeler, Edwin Silverman, Shete Sanjay, Spiridon Tsavachidis, Georgina Armstrong, Elena Kupert, Marshall Anderson, Yafang Li, Claudio Pikielny, Joan E. Bailey-Wilson, Ming You, Colette Gaba, Mariza DeAndrade, Diptasri Mandal, Claire Simpson, Susan Pinney, Christopher Amos, Margaret Spitz. Target exome sequencing for disease-causing rare mutations in familial and sporadic lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4600. doi:10.1158/1538-7445.AM2015-4600